10x Genomics (TXG) Equity Average (2018 - 2026)

10x Genomics has disclosed Equity Average across 9 years of filings, most recently posting $805.3 million for Q1 2026.

• Equity Average for Q1 2026 came in at $805.3 million, up 13.66% year-over-year; the trailing twelve-month figure through Mar 2026 was $805.3 million (up 13.66% YoY), and the FY2025 annual result was $753.2 million, up 3.81% from the prior year.
• Equity Average came in at $805.3 million for Q1 2026 at 10x Genomics, up from $790.7 million in the prior quarter.
• In the past five years, Equity Average ranged from a high of $812.1 million in Q1 2022 to a low of $708.5 million in Q1 2025.
• The 5-year median for Equity Average is $779.2 million (2025), against an average of $765.1 million.
• Across the five-year window, Equity Average fell 9.58% in 2024 and increased 13.66% in 2026, its largest moves.
• 10x Genomics' Equity Average stood at $790.8 million in 2022, then fell by 6.02% to $743.1 million in 2023, then retreated by 3.59% to $716.5 million in 2024, then grew by 10.36% to $790.7 million in 2025, then climbed by 1.85% to $805.3 million in 2026.
• The last three Equity Average figures came in at $805.3 million (Q1 2026), $790.7 million (Q4 2025), and $779.2 million (Q3 2025), per Business Quant data.